文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔注射康柏西普治疗早产儿视网膜病变的疗效

Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity.
PubMed 文献 · Br J Ophthalmol · 2018-07-20

该回顾性研究纳入2015年6月至2016年7月在珠江医院接受玻璃体腔康柏西普注射(IVC)的24例(48眼)早产儿视网膜病变(ROP)患者,主要结局为附加病变消退;结论认为IVC注射是ROP的有效治疗。

要点

  • 附加病变在首次注射后平均3.5±1.5周消退。
  • 8眼(16.7%)复发,4眼接受第二次IVC,4眼接受激光光凝,附加病变均在3周内消退。

核心结论

  • IVC注射是治疗早产儿视网膜病变的有效方法。

研究设计与样本

  • 回顾性研究纳入2015年6月至2016年7月在珠江医院接受IVC注射的ROP患者,共24例48眼。

主要发现

  • 48眼中9眼(5例)为I区ROP,35眼(18例)为II区ROP,4眼(2例)为急进性后部ROP。
  • 平均胎龄28.5±1.6周,平均出生体重1209.6±228.6 g,首次注射平均矫正胎龄34.2±1.9周,平均随访31.0±4.7周。
  • 8眼(16.7%)复发,其中4眼接受第二次IVC、4眼接受激光光凝,附加病变均在3周内消退。
  • 随访期间未观察到晶状体混浊、玻璃体积血、眼球萎缩或视网膜脱离。

临床怎么用

  • IVC注射可用于ROP治疗,本研究中多数患眼单次注射后附加病变消退。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the safety and efficacy of intravitreal conbercept (IVC) injection in the treatment of retinopathy of prematurity (ROP). METHODS: Patients with ROP who underwent IVC injection in Zhujiang Hospital from June 2015 to July 2016 were studied retrospectively. The primary outcome was defined as the regression of plus disease. The secondary outcomes were defined as the presence of recurrence, number of injections and the final regression of disease. RESULTS: A total of 48 eyes of 24 patients with ROP were included. Among them, 9 eyes of 5 patients had zone I ROP, 35 eyes of 18 patients had zone II ROP and 4 eyes of 2 patients had aggressive posterior ROP. The mean gestational age was 28.5±1.6 weeks, the mean birth weight was 1209.6±228.6 g, the mean postmenstrual age of first injection was 34.2±1.9 weeks and the mean follow-up period was 31.0±4.7 weeks. Forty of 48 eyes (83.3%) received IVC only once, and the regression of plus disease occurred at an average of 3.5±1.5 weeks after the first injection of conbercept. For eight recurrent eyes (16.7%), four eyes received a second IVC and the remaining four eyes received laser photocoagulation, and the regression of plus disease occurred in 3 weeks. No lens opacity, vitreous haemorrhage, entophthalmia or retinal detachment was observed during follow-up. CONCLUSION: IVC injection is an effective treatment for ROP.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bai Y, Nie H, Wei S, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol. 2018. PMID: 30030391. doi:10.1136/bjophthalmol-2017-311662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。